Chicago-based AbbVie announced new data for Mavyret (glecaprevir/pibrentasvir), a pan-genotypic treatment for chronic HCV in treatment-naive patients with compensated cirrhosis.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Merck & Co.’s blockbuster drug Keytruda met the main goal of a late-stage trial testing the treatment in patients with cancers of the digestive tract.
As an outbreak of the Ebola virus in the Democratic Republic of the Congo worsens, a team of health officials took four experimental vaccines to the front lines and began to administer it to patients who may have been exposed to the deadly virus.
Clinical data for a fish-oil-based drug from Amarin Corporation confirmed the drug’s ability to reduce the relative risk reduction of adverse cardiovascular events by 25 percent, including a 20 percent reduction in cardiovascular death.
The largest clinical trial so far to assess a new class of diabetes pills shows that AstraZeneca’s Farxiga can prevent heart failure and cut the risk of kidney problems in a broad range of patients.
Eli Lilly scrapped a Phase II clinical trial for N3pG, a humanized IgG1 monoclonal antibody, plus BACE in the treatment of Alzheimer’s.
Endo International Plc expects to launch the company’s treatment for cellulite in the second half of 2020, a day after announcing results from two late-stage trials testing the drug.
Foamix Pharmaceuticals’ experimental foam treatment FMX103 for rosacea met the main goals of two late-stage studies.
Aveo Oncology’s Phase III study of tivozanib for highly refractory advanced or metastatic renal cell carcinoma (RCC) met the primary endpoint of demonstrating a statistically significant benefit in PFS.
Eli Lilly.’s top-selling diabetes drug Trulicity significantly reduced the risk of heart attack, stroke and heart-related death in a broad range of people with type 2 diabetes in a large clinical trial.
AbbVie and Roche’s targeted therapy delayed the progression of a type of blood and bone marrow cancer when used in combination with the Swiss drugmaker’s cancer drug in a late-stage trial.
A once-monthly injection to control HIV proved as effective as daily pills in a second study by GlaxoSmithKline, paving the way for a new regimen that could be simpler for some patients.
Denmark-based Genmab released top-line data from the Phase III MAIA clinical trial of Darzalex (daratumumab), a drug licensed to Johnson & Johnson’s Janssen.
Lundbeck’s shares plunged after announcing the new drug candidate Lu AF35700 for treatment-resistant schizophrenia failed to differentiate itself against conventional therapies in Phase III.
Ultragenyx shares were down after announcing the Phase III drug candidate UX007 failed to hit the mark as a treatment for patients with glucose transporter type-1 deficiency syndrome (Glut1 DS) who are experiencing disabling paroxysmal movement disorders.
German’s Bayer and Finland’s Orion said a study showed the prostate cancer drug darolutamide that the companies are developing can delay the spread of the disease to other body parts.
Tanezumab, a non-opioid drug developed by Pfizer and Eli Lilly, met the main goals of a late-stage study in which over half of patients reported a significant reduction in hip or knee osteoarthritis pain.
Upadacitinib, in development for rheumatoid arthritis (RA), showed significant improvement in physical function, pain and quality of life versus the commonly prescribed generic methotrexate.
Cambridge, Mass.-based Biogen and Brussels, Belgium-based UCB’s Phase IIb trial of dapirolizumab pegol in lupus failed to hit the primary endpoint, however, the study did show some efficacy and met other secondary endpoints.